Lefamulin BC3781, CAS 1061337-51-6, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains in comparison to azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin. Lefamulin was highly active against all strains tested, with all MICs ≤ 0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.
The designation has been granted for lefamulin to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).
Hot Tags: Modafinil, SEX hormones.
Lefamulin BC3781 (CAS 1061337-51-6) Basic information
Synonyms:Lefamulin;2-[[(1R,2R,4R)-4-Amino-2-hydroxycyclohexyl]thio]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester;BC 3781
H Bond Donors: 3
H Bond Acceptors: 5
Rotatable Bonds: 6
Therapeutic Class: Antibiotic, other; Phase III Clinical Trial